Volker Haucke receives the Ernst Schering Prize 2025
The Ernst Schering Prize 2025, endowed with 50.000 euros, is awarded to Prof. Dr. Volker Haucke, Director at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Professor of Molecular Pharmacology at Freie Universität Berlin. This prestigious science award honors his groundbreaking discoveries on the function of signaling lipids, which control the cellular responses to messengers, hormones, and nutrients, thereby shaping central processes in cell communication. weiter
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, through Novartis Pharma K.K. which will oversee product distribution and safety information management as the Designated Marketing Authorization Holder for GalliaPharm® in Japan. weiter
Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price target of € 24.00. This corresponds to a price potential of 46.8% compared to the Xetra closing price of € 16.35 on 8 September 2025. weiter
Promoting awareness of health research
During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Center, Charité – Universitätsmedizin Berlin, the German Center for Child and Adolescent Health and others. weiter
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 clinical trial of ART-101 in the United States, with manufacturing to be performed at Eckert & Ziegler’s state-of-the-art GMP facility in Boston, MA. weiter
Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. weiter
Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite
The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply. weiter
Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023 and from 2023 to 2025. In addition to successfully fulfilling all mandatory criteria, Eckert & Ziegler also scored highly in the voluntary and excellence criteria thanks to its long-standing commitment to training. weiter
The Long Night of the Sciences 2025
The Long Night of the Sciences has been a Berlin tradition for 25 years – and the Max Delbrück Center and Campus Berlin-Buch have been part of it from the very beginning. On June 28, we celebrated this milestone with science enthusiasts, families, and special guests. weiter
Students from Freie Universität Berlin visited the Campus Berlin-Buch
Visiting the Campus Berlin-Buch: Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025. weiter
Berlin-Buch goes Boston
At BIO 2025, June 16-19 in Boston, Campus Berlin-Buch GmbH will be showcasing the location of future innovation Berlin-Buch weiter
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor. weiter
Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event gathered around 100 decision makers, renowned experts, key partners, and influential industry leaders to explore the transformative potential of radionuclides in precision oncology. weiter
Knowledge for your ears
The Life Science Learning Lab has launched a new podcast intended to spark young people’s interest in research. During the first three episodes of “scienceCLASH,” students from Berlin interviewed Sarah Kedziora and Theda Bartolomaeus from the ECRC about the gut microbiome’s influence on heart health. weiter
Eckert & Ziegler Wins “Best Managed Companies Award” for the Second Time
Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI), recognize excellently managed medium-sized companies throughout Germany. Eckert & Ziegler has now received this coveted award the second time. weiter
Talk im Cube: International Cooperation and Funding programs in Life Sciences
We are excited to continue also in 2025 the Talks in the Cube starting with a further expert discussion focused on International cooperation and Funding programs in Life Sciences. weiter
Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. weiter
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further develop its promising lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. weiter
Event: Cutting-Edge Biomarker Profiling in clinical studies: A Lunch and Learn with CheckImmune and Olink®
A Lunch and Learn with CheckImmune and Olink® weiter
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing. weiter
“Jugend forscht” at Campus Berlin-Buch
From better 3D printers for biological structures to soil remediation with microorganisms – in the 60th round of “Jugend forscht,” regional students presented their exciting research projects on the Berlin-Buch campus. weiter
Access to high-performance computing for businesses
Helmholtz invests €18 million in AI innovation ecosystems: Nine Helmholtz centers open their High-Performance Computing infrastructure to companies and connect businesses with their AI experts. More than €2 million will go to the Max Delbrück Center. weiter
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC). weiter
